Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Taito FukushimaManabu MorimotoSatoshi KobayashiMakoto UenoHaruki UojimaHisashi HidakaChika KusanoMakoto ChumaKazushi NumataKota TsuruyaYoshitaka AraseTatehiro KagawaNobuhiro HattoriHiroki IkedaTsunamasa WatanabeKatsuaki TanakaShin MaedaPublished in: The oncologist (2023)
The development of irAEs was associated with increased survival in a real-world population of patients with advanced HCC treated with atezolizumab plus bevacizumab. Grade 1/2 irAEs were strongly correlated with PFS and OS.